Stem cell therapy (MSC IV) — Systemic Cellular Rejuvenation

Mesenchymal stem cells (MSCs) exert systemic anti-aging effects primarily through paracrine signaling rather than direct cellular engraftment. They secrete a complex secretome of exosomes, cytokines, and growth factors that modulate the immune system, reducing chronic systemic inflammation (inflammaging). MSCs also promote tissue regeneration by stimulating endogenous progenitor cells, enhancing angiogenesis, and transferring healthy mitochondria to damaged cells via tunneling nanotubes. Furthermore, they have been shown to reduce oxidative stress and potentially clear senescent cells, thereby restoring tissue homeostasis.

Multiple phase I/II trials have evaluated intravenous allogeneic mesenchymal stem cells for aging frailty. A landmark 2017 trial (Tompkins et al.) showed improvements in physical performance and inflammatory markers (TNF-α) with no serious adverse events. However, long-term durability of these effects remains uncertain, and larger phase III trials are needed to confirm efficacy for longevity.

100 to 200 million cells per infusion is the most common range in clinical trials for aging frailty. Administered intravenously over 1-2 hours. In the US, MSC therapies are not FDA-approved for anti-aging and are often administered in offshore clinics or under investigational protocols.

Generally well-tolerated in clinical trials with mild, transient infusion reactions being the most common adverse events. However, theoretical risks include ectopic tissue formation, immune rejection (though MSCs are immune-privileged), and potential promotion of existing undiagnosed malignancies due to their pro-angiogenic and immunosuppressive properties. Long-term safety data in healthy aging populations is lacking.

Key Papers